NCT02448329View on ClinicalTrials.gov

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 14, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

April 19, 2021

Conditions
Advanced Gastric Adenocarcinoma
Interventions
DRUG

AZD1775

AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1\~3

DRUG

paclitaxel

paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle

Trial Locations (1)

135-710

Samsung Medical center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02448329 - Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy | Biotech Hunter | Biotech Hunter